Ligand Pharmaceuticals (LGND) Says Glaxo (GSK) Submits Regulatory Apps for Promacta/Revolade

Ligand Pharmaceuticals (Nasdaq: LGND) partner GlaxoSmithKline plc (NYSE: GSK) has submitted regulatory applications in the United States and European Union related to eltrombopag (Promacta/Revolade) and its use to increase platelet counts in patients with chronic hepatitis C virus infection and low platelets (thrombocytopenia), specifically:

• A supplemental New Drug Application to the US Food and Drug Administration for Promacta (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and to optimize interferon-based therapy.
  
  
• A variation to the Marketing Authorization Application to the European Medicines Agency for Revolade (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and during interferon-based therapy.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• EU approves Gilead's Trodelvy combo with Keytruda for front-line TNBC
• Faraday Future signs robotics distributor deal, plans partner event
• Extra Space Storage names Noah Springer as next CEO